SCHEMBL16670438

SCHEMBL16670438

COCOc1ccc(O)c(O)c1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 3/20 0.40
HIF1A Q16665 1/20 0.39
EPAS1 Q99814 1/20 0.39
MAPT P10636 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
CYP3A4 P08684 1/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
ALOX12 P18054 1/20 0.36
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PTPN1 P18031 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16670210 0.81 MAPT (0.36) HIF1AEPAS1MAPTKDM4EALDH1A1
SCHEMBL31643652 0.78 MAPT (0.51) MAPTCYP2C9CYP2C19SMN1; SMN2TDP1
SCHEMBL17574341 0.78 MAPT (0.62) MAPTCYP2C9CYP2C19SMN1; SMN2TDP1
SCHEMBL10088414 0.78 ERN1 (0.44) BACE1MAPTCYP2C9CYP2C19SMN1; SMN2
SCHEMBL7861678 0.77 HIF1A (0.55) HIF1AEPAS1MAPTKDM4EALDH1A1
SCHEMBL3221392 0.76 MAPT (0.47) MAPTCYP2C9CYP2C19SMN1; SMN2TDP1
SCHEMBL23041032 0.76 LMNA (0.59) BACE1MAPTKDM4EALDH1A1LMNA
SCHEMBL15287726 0.75 PTPN1 (0.39) MAPTKDM4EALDH1A1LMNATP53
SCHEMBL17559171 0.75 MAPT (0.39) BACE1MAPTHSD17B10CYP2C9CYP2C19
SCHEMBL16242750 0.75 GRM2 (0.48) MAPTCYP2C9CYP2C19SMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2861572-B1 IMPROVED PROCESS FOR THE PREPARATION OF 2-SUBSTITUTED-2-(6-(SUBSTITUTED)-7-METHYLBENZO[D][1,3]DIOXOL-4-YL)ACETIC ACID DERIVATIVES NATCO PHARMA LTD (IN) 2018-10-31 EP disclosed
US-9227948-B2 Process for the preparation of 2-substituted-2-(6-(substituted)-7-methylbenzo[D][1,3]dioxol-4-yl)acetic acid derivatives NATCO PHARMA LIMITED (IN) 2016-01-05 US disclosed
US-9227948-B2 Process for the preparation of 2-substituted-2-(6-(substituted)-7-methylbenzo[D][1,3]dioxol-4-yl)acetic acid derivatives NATCO PHARMA LIMITED (IN) 2016-01-05 US disclosed
US-9227948-B2 Process for the preparation of 2-substituted-2-(6-(substituted)-7-methylbenzo[D][1,3]dioxol-4-yl)acetic acid derivatives NATCO PHARMA LIMITED (IN) 2016-01-05 US disclosed
US-20150119587-A1 PROCESS FOR THE PREPARATION OF 2-SUBSTITUTED-2-(6-(SUBSTITUTED)-7-METHYLBENZO[D][1,3]DIOXOL-4-YL)ACETIC ACID DERIVATIVES NATCO PHARMA LIMITED (IN) 2015-04-30 US disclosed
US-20150119587-A1 PROCESS FOR THE PREPARATION OF 2-SUBSTITUTED-2-(6-(SUBSTITUTED)-7-METHYLBENZO[D][1,3]DIOXOL-4-YL)ACETIC ACID DERIVATIVES NATCO PHARMA LIMITED (IN) 2015-04-30 US disclosed
US-20150119587-A1 PROCESS FOR THE PREPARATION OF 2-SUBSTITUTED-2-(6-(SUBSTITUTED)-7-METHYLBENZO[D][1,3]DIOXOL-4-YL)ACETIC ACID DERIVATIVES NATCO PHARMA LIMITED (IN) 2015-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119587-A1 PROCESS FOR THE PREPARATION OF 2-SUBSTITUTED-2-(6-(SUBSTITUTED)-7-METHYLBENZO[D][1,3]DIOXOL-4-YL)ACETIC ACID DERIVATIVES DERA, XDH, F12 BACE1 3575/4885HIF1A 438/4885EPAS1 1992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.